It is a first-in-class medication approved by the European Commission and the U.S. Food and Drug Administration (FDA) for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL)[1][3][5]. Market Size and Growth The BESPONSA ...